-Firstpost.com After the UPA-II released its self-congratulatory 79-page ‘Report card to the People', National Advisory Council (NAC) member and leading social activist Aruna Roy has come down heavily on the government for its poor performance in the social sector. Roy, an instrumental force behind the Right to Information Act, criticised the government for stalling on essential legislations such as the Food Security Bill, the Land Acquisition Bill and the Lokpal Bill. Roy spoke...

-The Times of India NEW DELHI: Four million households in Maoist-affected districts are likely to get BPL status without having to wait for another two years when the Socio-Economic Caste Census is expected to be completed. The list of BPL will be revised based on the findings of the census. The shortcut inclusion in the 82 Maoist-affected districts is aimed at making the poor, who fell between the cracks of the poverty...

-The Times of India NEW DELHI: The comptroller and auditor general has started conducting secret studies, called management reports, which are not tabled in Parliament. Starting with a report on Commonwealth Games (CWG), four such reports have been out. In the form of advisories, these reports are meant to forewarn the government on systematic faults and alert the departments to adopt fiscal prudence. Besides the one on CWG, the official auditor has produced...

-The Telegraph The sudden arrest of Amway India's top brass on Monday has focused the spotlight on the crumbling fault lines and the grey areas in the demarcation between some of the world's best-known direct selling companies and the dodgy Ponzi schemes that promise huge returns to gullible investors and have lately grabbed all the sensational headlines in Bengal. William S. Pinckney, managing director of Amway India, and two directors of the...

-The Business Standard USFDA's zero tolerance policy requires our drug firms to reorient not just processes but organisational cultures to serve that market credibly The following two quotes from the United States Food and Drug Administration (FDA) news releases may help put the Ranbaxy controversy in perspective. The first sums up what it is that drives the FDA and the second is typical of the challenge the pharmaceutical industry faces. (1) "The consent...